Результаты поиска

Application of wearables for remote monitoring of oncology patients: A scoping review.

ObjectiveThis review aims to systematically map and categorize the current state of wearable applications among oncology patients and to identify determinants impeding clinical implementation.MethodsA Medline, Embase and clinicaltrials.gov search identified journal articles, conference abstracts, letters, reports, dissertations and registered studies on the use of wearables in patients with malignancies published up to 10 November 2021.ResultsOf 2509 records identified, 112 met the eligibility criteria. Of these, 9.8% (11/112) were RCTs and 47.3% (53/112) of publications were observational. We

Comparative single-cell multiplex immunophenotyping of therapy-naive patients with rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus shed light on disease-specific composition of the peripheral immune system.

INTRODUCTION: Systemic autoimmune diseases (SADs) are a significant burden on the healthcare system. Understanding the complexity of the peripheral immunophenotype in SADs may facilitate the differential diagnosis and identification of potential therapeutic targets. METHODS: Single-cell mass cytometric immunophenotyping was performed on peripheral blood mononuclear cells (PBMCs) from healthy controls (HCs) and therapy-naive patients with rheumatoid arthritis (RA), progressive systemic sclerosis (SSc), and systemic lupus erythematosus (SLE). Immunophenotyping was performed on 15,387,165 CD45+

Current state of CAR-T therapy for T-cell malignancies.

Chimeric antigen receptor T-cell (CAR-T) therapy has been approved for relapsed/refractory B-cell lymphomas and greatly improves disease outcomes. The impressive success has inspired the application of this approach to other types of tumors. The relapsed/refractory T-cell malignancies are characteristic of high heterogeneity and poor prognoses. The efficacy of current treatments for this group of diseases is limited. CAR-T therapy is a promising solution to ameliorate the current therapeutic situation. One of the major challenges is that normal T-cells typically share mutual antigens with mali

Abstracts of the 3rd International Conference on Cancer Cachexia, September 23–25, 2016 in Washington, DC, USA

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma.

Multiple myeloma (MM), the second most common hematologic cancer, is caused by accumulation of aberrant plasma cells in the bone marrow. Its molecular causes are not fully understood and its great heterogeneity among patients complicates therapeutic decision-making. In the past decades, development of new therapies and drugs have significantly improved survival of MM patients. However, resistance to drugs and relapse remain the most common causes of mortality and are the major challenges to overcome. The advent of high throughput omics technologies capable of analyzing big amount of clinical a

The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings.

BACKGROUND: This research aimed to quantify the burden of illness (BoI) in transplant eligible (TE) and transplant non-eligible (TNE) newly diagnosed multiple myeloma (NDMM) patients and their caregivers, in the first year after diagnosis: at months 0, 3, and 12. METHODS: Prospective, cross-sectional, observational NDMM study of TE and TNE patients and their caregivers from France, Germany, Italy, and Spain was conducted between May 2019 and January 2021. A structured, online questionnaire measuring disease burden, direct and costs, out-of-pocket expenses, and health-related quality of life (

Joint Clinical Assessment in the EU HTA Regulation-Would Drugs Supported by Single-Arm Trials Fit Under Evaluation?

The Joint Clinical Assessment (JCA) evaluates the relative effectiveness (RE) of interventions over comparators. While randomised control trials (RCTs) are considered the gold standard, single-arm trials (SATs) require an external control for accurate RE estimation. This study reviewed Health Technology Assessment (HTA) outcomes for medicinal products supported by SATs in France, Germany, Poland, and Spain, and simulated the JCA for these products based on evidence submitted in France. Among HTA evaluations published in France in 2019-2024, 16% were SAT-driven, and 5.6% of them included extern

Down-regulation of EHMT2 through irisin-mediated epigenetic modification promotes osteogenesis via promoting DLX3 transcription.

BACKGROUND: Irisin, a cleavage peptide by fibronectin type III domain-containing protein 5 (FNDC5), has been recognized as a promotor of osteogenesis to alleviate osteoporosis (OP). However, the detailed regulatory mechanism of osteogenesis remains unclear. This study uncovered the mechanisms underlying bone formation. METHODS: Osteogenic activity was evaluated by ALP and ARS staining. Expression of target molecules and osteogenic-related factors was assessed by RT-qPCR, Western blotting, and immunohistochemical staining. The binding of euchromatic histone lysine methyltransferase 2 (EHMT2) to

Novel diagnostic approaches and therapeutic management of mucormycosis: insights from a retrospective monocentric cohort study.

BACKGROUND: Mucormycosis is a rare, opportunistic fungal infection with high mortality rates, predominantly affecting immunocompromised patients. Its management is challenging due to diagnostic complexity and limited therapeutic options. METHODS: This retrospective cohort study analyzed 21 cases of mucormycosis diagnosed at the University Hospital of Liège between July 2018 and August 2023. Clinical, microbiological, and radiological data were evaluated to identify risk factors, treatment modalities, and outcomes. RESULTS: Hematological malignancies (82%) and immunosuppressive therapy (53%)

Активация клеток, похожих на ретинальный макрофаж, и разбавление слоя ячеек связаны с инвалидностью и МРТ-повреждением при множественном склерозе.

Множественный склероз — хроническая нейро-воспалительная болезнь, при которой клетки, подобные микроглии и макрофаге, играют центральную роль в прогрессии заболеваний. Сетчатка как центральная нервная система, доступная для неинвазивной съемки, открывает уникальное окно в эти процессы. ЦЕЛЬ: Цель этого исследования состояла в том, чтобы определить, связаны ли характеристики клеток сетчатки с макрофагом и толщиной клеточного слоя с клинической инвалидностью и ударом магнитного резонанса у пациентов с множественным склерозом.МЕТОДЫ: В ходе этого перекрестного наблюдения пациенты, страдающие множ

Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myeloma.

CT103A is a fully human chimeric antigen receptor T cell (CAR-T) product for targeting B cell maturation antigen. This study presents the updated safety and efficacy profiles of CT103A in patients with relapsed/refractory multiple myeloma (RRMM) after long-term follow-up. As of July 31, 2023, the median follow-up time after CAR-T cell infusion was 45.0 months (range, 0.7-58.3 months). During long-term follow-up, the incidence of adverse events gradually decreased over time. One patient had a maximum duration of response of nearly 5 years. All 18 patients (100%) achieved partial remission or be

Identified Medications Causing Medication-Related Osteonecrosis of the Jaw: A Literature Review.

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse event that occurs in patients treated with certain medications, leading to a major side effect that can result in substantial morbidity. MRONJ is known to be associated with antiresorptive (AR) and antiangiogenic (AA) medicines, but recent evidence suggests that other medications may also be involved. Recognizing a broad range of drug-induced risk factors is important, notably in light of the increasing number of drugs associated with MRONJ. The primary objective of this review is to update and synthesize findings from th

Полиморфизм меланкортина - генезиалы с воспалением и болезнями.

Рецепторы Меланокортина (МКР) выполняют различные функции: от пигментации кожи, регулирования аппетита, реакции на стресс и когниции, синтеза стероидов и энергетического баланса до регенерации клеток и иммуномодуляции. Генетический полиморфизм с распределением тканей от мозга, лимбической системы и адренальной коры до нейтрофилов, моноцитов и макрофазов проявляется в MCR. Мутации в генах MC1R, MC2R, MC3R и MC4R связаны с риском меланомы, семейной глюкокортикоидной недостаточности, ожирения и типа 2 Диафиозный сахар, соответственно. Тем временем, MC1R, MC2R и MC5R связаны с риском серьезного де

Центральная ингибиция TYK2 идентифицирует TYK2 как ключевой нейроиммунный модулятор.

GWAS выявила тирозиновую киназу 2 (TYK2) в многочисленных провокационных расстройствах, в частности защитную гипоморфическую аллею TYK2 (P1104A) в множественных склерозах (MS). Поврежденный TYK2 сигнал в центральной нервной системе (CNS) может вызывать защитное воздействие аллеля TYK2 P1104A в MS. Мы использовали ингибиторы TYK2 (cTYK2i) в дополнение к периферически ограниченному ингибитору TYK2 (pTYK2i; BMS-986165) для того, чтобы рассеять влияние центрального ингибитора TYK2 в различных моделях нейроинфламмации. В то время как PTYK2i не оказывал существенного воздействия, cTYK2i уменьшили кл

Ранняя реакция на рост Gene 1 Выгоды Аутоиммунная болезнь путем поощрения дифференциации ячеек в качестве регулятора Foxp3.

Foxp3+ Регулирующие T (Treg) клетки, как один из подтипов CD4+T клеток, являются важнейшим сторожем в патогенезе самоантигенных реактивных заболеваний. В этом контексте мы продемонстрировали, что выборочная абляция гена раннего реагирования роста 1 (Egr-1) в CD4+T клеток усугубила экспериментальный аутоиммунный энцефаломиелит (EAE) в мюриновых моделях. Отсутствие Egr-1 в клетках CD4+T, полученное из мышей EAE и наивных клеток CD4+T, препятствовало дифференциации и влиянию Treg. Важно то, что в CD4+T клеток нескольких склерозных пациентов как Egr-1, так и Foxp3 было обнаружено снижение. Дальней

Nomograms Predict PFS and OS for SCLC Patients After Standardized Treatment: A Real-World Study.

PurposeThis study aims to investigate the process of small cell lung cancer (SCLC) patients from achieving optimal efficacy to experiencing disease progression until death. It examines the predictive value of the treatment response on progression free survival (PFS) and overall survival (OS) of SCLC patients.Patients and methodsWe conducted a retrospective analysis on 136 SCLC patients diagnosed from 1992 to 2018. Important prognostic factors were identified to construct nomogram models. The predictive performance of the models was evaluated using the receiver operating characteristic curves a

Совпадение в полном тексте источника
… This study was a retrospective analysis of clinical practice and did not collect patients’ informed consent forms. …

Antiseptic Functions of CGK012 against HMGB1-Mediated Septic Responses.

High mobility group box 1 (HMGB1), a protein with important functions, has been recognized as a potential therapeutic target for the treatment of sepsis. One possible mechanism for this is that inhibiting HMGB1 secretion can exert antiseptic effects, which can restore the integrity of the vascular barrier. (7S)-(+)-cyclopentyl carbamic acid 8,8-dimethyl-2-oxo-6,7-dihydro-2H,8H-pyrano[3,2-g]chromen-7-yl-ester (CGK012) is a newly synthesized pyranocoumarin compound that could function as a novel small-molecule inhibitor of the Wnt/β-catenin signaling pathway. However, no studies have yet determi

Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more.

Clinical endpoints, such as overall survival, directly measure relevant outcomes. Surrogate endpoints, in contrast, are intermediate, stand-in measures of various tumour-related metrics and include tumour growth, tumour shrinkage, blood results, etc. Surrogates may be a time point measurement, that is, tumour shrinkage at some point (eg, response rate) or biomarker-assessed disease status, measured at given time points (eg, circulating tumour DNA, ctDNA). They can also be measured over time, as with progression-free survival, which is the time until a patient presents with either disease progr

Evaluation of epidemiological and pathological features of symptomatic spinal metastases in Romania - what could we learn from a retrospective study?

Metastases are the most common tumors of the spine. As an important increase in the annual incidence of spinal metastases (SMs) has been observed in the last decade, the aim of this study was to describe the epidemiology and histopathological types of SMs surgically treated in the Neurosurgery Clinics of a Regional Hospital in North-Eastern Romania over a period of five years, in order to define a certain tumor profile that would benefit from an early screening. We retrospectively evaluated 115 adult patients, searching for demographic data (gender and age of the patients), primary tumor chara

Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy.

Triple-negative breast cancer (TNBC) is a heterogeneous disease with varying responses to neoadjuvant chemotherapy (NAC). The identification of biomarkers to predict NAC response and inform personalized treatment strategies is essential. In this study, we conducted large-scale gene expression meta-analyses to identify genes associated with NAC response and survival outcomes. The results showed that immune, cell cycle/mitotic, and RNA splicing-related pathways were significantly associated with favorable clinical outcomes. Furthermore, we integrated and divided the gene association results from